Type 1 Diabetes - News, Articles etc. - European Pharmaceutical Review
FDA Approves Empagliflozin for Reducing Risk of Heart Failure | DAIC
FDA Approves Diabetes Medication for Heart Failure - Diabetes Education Services
U.S. FDA Accepts Filing of Cardiovascular Outcomes Data for Jardiance® ( empagliflozin)
FDA rejects lower-dose empagliflozin 2.5 mg for type 1 diabetes
10 Diabetes Medications That Cause Weight Gain (or Loss) - GoodRx
JCM | Free Full-Text | Physicians’ Considerations and Practice Recommendations Regarding the Use of Sodium-Glucose Cotransporter-2 Inhibitors
SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks - The Lancet Diabetes & Endocrinology
FDA approves first triple combination pill for type 2 diabetes
Biology | Free Full-Text | Differential Effects of Empagliflozin on Microvascular Complications in Murine Models of Type 1 and Type 2 Diabetes
Week in Review: FDA OKs First Drug to Delay Type 1 Diabetes, Low-Protein Diet Linked to Obesity, and More
SGLT-1/2-Hemmer auch bei Typ-1-Diabetes? - Der niedergelassene Arzt
HIM.PA.91 Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors
US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction
Pharmakovigilanz: Gliflozin-Nutzen überwiegt das Risiko
FDA approves Synjardy for adults with type 2 diabetes
Lexicon Fires Back after Sanofi Ends Up-to-$1.7B Diabetes Collaboration
Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus - The Lancet Diabetes & Endocrinology
FDA blocks Lilly, Boehringer's Jardiance from coveted Type 1 diabetes nod | Fierce Pharma
Empagliflozin approved to treat diabetes - Clinical Advisor
